US2004259253A1PendingUtilityA1

Vectors for gene mutagenesis and gene discovery

Assignee: LEXICON GENETICS INCPriority: Mar 27, 1998Filed: Mar 9, 2004Published: Dec 23, 2004
Est. expiryMar 27, 2018(expired)· nominal 20-yr term from priority
C12N 2840/203C12N 2840/20C12N 15/86C12N 2740/13043C12N 15/1037C40B 40/02C12N 15/85C12N 2740/10043C12N 2800/60C12N 2840/44C12N 15/1051C12N 15/1034C12N 2800/30
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel vectors are described that incorporate, inter alia, a novel 3′ gene trap cassette that does not encode a marker conferring antibiotic resistance and which can be used to efficiently trap, mutagenize, and identify previously unknown cellular genes. Vectors incorporating the presently described 3′ gene trap cassette find particular application in gene discovery, and the production of mutated cells and animals.

Claims

exact text as granted — not AI-modified
1 - 20 . (Canceled)  
     
     
         21 . A method of producing a transgenic mouse comprising a vector, comprising 
 a) introducing a vector into murine embryonic stem (ES) cells, wherein the vector comprises: 
 i) a 5′ gene trap cassette, comprising in operable combination: 
 1) a splice acceptor;  
 2) a first exon sequence located 3′ to said splice acceptor, said first exon sequence encoding a marker enabling the identification of a cell expressing said first exon sequence; and  
 3) a polyadenylation sequence located at the 3′ end of said first exon sequence;  
 
 ii) a 3′ gene trap cassette located 3′ to said polyadenylation sequence, comprising in operable combination: 
 1) a first promoter;  
 2) a second exon sequence located 3′ from and expressed by said first promoter, said second exon sequence not encoding an activity conferring antibiotic resistance;  
 3) a splice donor sequence located at the 3′ end of said second exon sequence; and  
 
    wherein said vector does not encode a promoter mediating the expression of said first exon sequence, and wherein said vector does not encode a sequence that mediates the polyadenylation of an mRNA transcript encoded by said second exon sequence;    b) selecting a murine ES cell that comprises the vector; and    c) making a transgenic mouse comprising the vector from the selected murine ES cell that comprises the vector.    
     
     
         22 . The method of  claim 21 , wherein the vector from the selected murine ES cell that comprises the vector is non-homologously incorporated into the genome of at least one cell in the transgenic mouse.  
     
     
         23 . The method of  claim 22 , further comprising identifying at least one trapped cellular exon after (b).  
     
     
         24 . The method of  claim 22 , further comprising identifying at least one trapped cellular exon after (c).  
     
     
         25 . The method of  claim 21 , wherein the transgenic mouse comprising the vector is a somatic transgenic mouse.  
     
     
         26 . The method of  claim 21 , wherein the transgenic mouse comprising the vector is a germ line transgenic mouse.  
     
     
         27 . The method of  claim 21 , wherein the first exon sequence additionally encodes an internal ribosome entry site operatively positioned between said splice acceptor and an initiation codon of said first exon.  
     
     
         28 . The method of  claim 21 , wherein the vector additionally comprises in the region between said polyadenylation sequence and said first promoter at least one of a transcription termination sequence, a 3′ terminal exon, and a sequence encoding a self-cleaving RNA.  
     
     
         29 . The method of  claim 21 , wherein the marker encoded by the first exon sequence of the vector is selected from a marker conferring antibiotic resistance, a marker conferring antibiotic sensitivity, an enzymatic marker, a recombinase, and a fluorescent marker.  
     
     
         30 . The method of  claim 29  wherein the marker confers neomycin resistance.  
     
     
         31 . The method of  claim 21 , wherein the vector is selected from a viral vector and a retroviral vector.  
     
     
         32 . The method of  claim 23 , wherein the identifying at least one trapped cellular exon comprises: 
 a) obtaining a chimeric transcript resulting from splicing of the second exon sequence to a third exon sequence, wherein the third exon sequence is from the genome of the ES cell;    b) reverse transcribing said chimeric transcript to produce a cDNA template; and    c) determining the polynucleotide sequence of the cDNA template.    
     
     
         33 . The method of  claim 24 , wherein the identifying at least one trapped cellular exon comprises: 
 a) obtaining a chimeric transcript resulting from splicing of the second exon sequence to a third exon sequence, wherein the third exon sequence is from the genome of the transgenic mouse;    b) reverse transcribing said chimeric transcript to produce a cDNA template; and    c) determining the polynucleotide sequence of the cDNA template.    
     
     
         34 . A method of making a transgenic mouse comprising a vector, comprising 
 a) introducing a vector into murine embryonic stem (ES) cells, wherein the vector comprises a 3′ gene trap cassette, comprising in operable combination: 
 i) a promoter;  
 ii) an exon sequence located 3′ from and expressed by said first promoter, said exon sequence not encoding an activity conferring antibiotic resistance; and  
 iii) a splice donor sequence located at the 3′ end of said exon sequence;  
    wherein the vector does not encode a sequence that mediates the polyadenylation of an mRNA transcript encoded by said exon sequence;    b) selecting a murine ES cell that comprises the vector; and    c) making a transgenic mouse comprising the vector from the selected murine ES cell that comprises the vector.    
     
     
         35 . The method of  claim 34 , wherein the vector from the selected murine ES cell that comprises the vector is non-homologously incorporated into the genome of at least one cell in the transgenic mouse.  
     
     
         36 . The method of  claim 35 , further comprising identifying at least one trapped cellular exon after (b).  
     
     
         37 . The method of  claim 35 , further comprising identifying at least one trapped cellular exon after (c).  
     
     
         38 . The method of  claim 34 , wherein the transgenic mouse comprising the vector is a somatic transgenic mouse.  
     
     
         39 . The method of  claim 34 , wherein the transgenic mouse comprising the vector is a germ line transgenic mouse.  
     
     
         40 . The method of  claim 34 , wherein the exon sequence additionally encodes an internal ribosome entry site operatively positioned between said splice acceptor and an initiation codon of said exon sequence.  
     
     
         41 . The method of  claim 34 , wherein the vector additionally comprises in the region between said polyadenylation sequence and said promoter at least one of a transcription termination sequence, a 3′ terminal exon, and a sequence encoding a self-cleaving RNA.  
     
     
         42 . The method of  claim 34 , wherein the exon sequence encodes a marker selected from an enzymatic marker, a recombinase, and a fluorescent marker.  
     
     
         43 . The method of  claim 42  wherein the marker is a fluorescent marker.  
     
     
         44 . The method of  claim 34 , wherein the vector is selected from a viral vector and a retroviral vector.  
     
     
         45 . The method of  claim 36 , wherein the identifying at least one trapped cellular exon comprises: 
 a) obtaining a chimeric transcript resulting from splicing of the exon sequence from the vector to a second exon sequence, wherein the second exon sequence is from the genome of the ES cell;    b) reverse transcribing said chimeric transcript to produce a cDNA template; and    c) determining the polynucleotide sequence of the cDNA template.    
     
     
         46 . The method of  claim 37 , wherein the identifying at least one trapped cellular exon comprises: 
 a) obtaining a chimeric transcript resulting from splicing of the exon sequence from the vector to a second exon sequence, wherein the second exon sequence is from the genome of the transgenic mouse;    b) reverse transcribing said chimeric transcript to produce a cDNA template; and    c) determining the polynucleotide sequence of the cDNA template.

Join the waitlist — get patent alerts

Track US2004259253A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.